Aytu BioPharma (AYTU) to Release Quarterly Earnings on Wednesday

Aytu BioPharma (NASDAQ:AYTU) will post its quarterly earnings results after the market closes on Wednesday, November 13th.

Aytu BioPharma (NASDAQ:AYTU) last released its quarterly earnings results on Thursday, September 26th. The company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.37). The firm had revenue of $17.98 million for the quarter. Aytu BioPharma had a negative return on equity of 51.31% and a negative net margin of 19.56%.

Aytu BioPharma Price Performance

Aytu BioPharma stock opened at $1.84 on Thursday. The company has a quick ratio of 0.79, a current ratio of 0.99 and a debt-to-equity ratio of 0.39. Aytu BioPharma has a 52-week low of $1.81 and a 52-week high of $3.45. The firm has a market cap of $11.31 million, a PE ratio of -0.64 and a beta of -1.40. The company’s 50 day moving average is $2.31 and its two-hundred day moving average is $2.66.

About Aytu BioPharma

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.